Summmary
Introduction
Headache in general, and migraine in particular, form a common and often debilitating series of problems whose pathophysiology is poorly understood (Goadsby, 1994) . Laboratory (Goadsby et ai, 1991a) and recent clinical evidence (Weiller et al., 1995) points to the importance of the CNS in migraine. Recent therapeutic advances suggesting a role for 5HT| B/D -like agonists in the management of acute attacks of migraine (Goadsby et al., 199\b\ Subcutaneous Sumatriptan International Study Group, 1991) have stimulated interest in this class of compounds and in their mode of action. While the rationale for the development of sumatriptan was as a crania! vasoconstrictor (Saxena, 1991) © Oxford University Press 1996 this mode of action has recently been vigorously debated (Humphrey and Goadsby, 1994) .
There is little doubt, based on clinical observation, that the pain in migraine in some way involves trigeminal structures (Lance, 1993) . Moreover, the long-recognized vascular component of the syndrome has focused attention on the trigeminal innervation of the pain-sensitive intracranial structures, such as the dura mater and large vessels (Feindel et al., 1960; McNaughton, 1966) . It has been shown during neurosurgical procedures that mechanical or electrical stimulation of the dura mater or blood vessels of conscious humans leads to pain referred to the ophthalmic (first) division of the trigeminal nerve. Because responses seen in cats are the same as those seen in humans , and more specific to the cranial circulation, we have turned to intracranial vessel stimulation to model trigeminovascular nociception. The structures chosen, the superior sagittal sinus and middle meningeal artery, have the advantage of being both pain-sensitive in humans (Wolff, 1963) and of being largely innervated by small unmyelinated C fibres (Keller et al., 1985) . Stimulation of the superior sagittal sinus has been shown to alter CBF in the cat (Lambert et al., 1988) as well as lead to changes in neuropeptide levels (Zagami et al., 1990) similar to those seen in humans during migraine and cluster headache (Goadsby and Edvinsson, 1994; Fanciullacci et al., 1995) .
Sumatriptan is clearly a potent and relatively specific cranial vasoconstrictor (Humphrey et al., 1991) . Sumatriptan also potently blocks trigeminal-induced plasma protein extravasation (Moskowitz, 1992) and calcitonin gene-related peptide release in the cranial circulation (Goadsby and Edvinsson, 1993) . However, Moskowitz observed that exogenously administered substance P induced a plasma protein extravasation that was not blocked by sumatriptan (Buzzi and Moskowitz, 1990) and, similarly, in a model of chemical meningitis that both dihydroergotamine and sumatriptan blocked trigeminal nucleus c-Fos expression (Nozaki et al., 1992) . Furthermore, the conformationally restricted analogue of sumatriptan, CP122,288, can block plasma protein extravasation at a dose at which it has no vascular effects (Lee and Moskowitz, 1993) . These data taken together suggest that sumatriptan may act sufficiently at a prejunctional 5HT| D -like receptor to inhibit neural transmission without necessarily having a vascular effect. In these studies the superior sagittal sinus was mechanically dilated to determine whether sumatriptan was still effective in attenuating trigeminal neural traffic. This unique method offers the possibility to separate the vasoactive and neural properties of this class of compounds.
Methods
Cats were anaesthetized initially with halothane and then occhloralose (60 mg kg" 1 , intraperitoneally) (Sigma, St Louis, USA) and prepared for physiological monitoring. The femoral artery and vein were cannulated in order to measure blood pressure and heart rate and provide access for drug and fluid administration, respectively. Cardiovascular parameters and pupillary reaction to noxious pinching of the forepaw were used to determine the need for supplementary anaesthesia. The animals were endotracheally intubated, ventilated with 40% oxygen and paralysed after the surgical procedures with repeated doses of gallamine triethiodide (6 mg kg" 1 intravenously) (May and Baker, UK). Body temperature and end-expiratory CO 2 were monitored and maintained within physiological limits. The animals were mounted in a stereotactic frame and a circular midline craniotomy (2 cm in diameter) was performed for access to the superior sagittal sinus. The adjacent dura and falx were dissected parallel to the sinus over 10-15 mm. To prevent dehydration and for electrical insulation against the cortex, a paraffin bath was built with a dam of dental acrylic around the craniotomy and, additionally, a small polyethylene sheet inserted under the vessel. Fluid (4% glucose with 0.18% saline or normal saline) was administered intravenously at a rate of 35 ml kg" 1 h" 1 , while gallamine (6 mg kg" 1 intravenously) and achloralose (15 mg kg" 1 intravenously) were administered every 2 h. Prior to readministration of gallamine, adequacy of anaesthesia was monitored by observing cardiovascular and pupillary changes, and by checking the withdrawal reflex, after pinching the forepaw. Blood pressure and heart rate were stable and within physiological ranges for all animals throughout the whole experiment. Arterial blood gas parameters were monitored intermittently as a guide to the end-expiratory CO 2 output.
Study design and stimulation Electrical stimulation
Following completion of surgery the animal was maintained essentially undisturbed for the following 24 h. Animals were then randomized to have electrical stimulation or mechanical stimulation, the latter with or without treatment with sumatriptan (85 |ig kg" 1 , intravenously) or vehicle administered in a manner blind to the investigator performing the stimulation. After this resting phase the superior sagittal sinus (SSS) was stimulated. For electrical stimulation, the SSS was suspended over a pair of stainless steel hook electrodes. We have previously shown that this would, of itself, not provoke significant Fos activation (Kaube et al., 1993b) . The SSS was stimulated with a Grass S88 stimulator driving a stimulus isolation unit (SIU5A, Grass Instruments, Quincy, Mass., USA; 150 V, 250 us duration) at a rate of 0.3 s" 1 for 1 h.
Mechanical stimulation
For mechanical stimulation a device was custom made and some of its characteristics have been described (Kaube et al., 1992) . It consisted of a stainless steel stimulator with a vertical hollow shaft, held fixed to a small brass plate, with an inner thinner steel rod connected to a small solenoid. During stimulation the inner rod moved in relationship to the fixed outer piece creating a vertical displacement that distended the sinus. Both pieces were bent to 90°, mounted on a stereotaxic carrier (Kopf Instruments, Tunjunga, Calif., USA) and inserted into the sinus under microscopic control after a small cut was made for entry. With practice, insertion was achieved with very minimal blood loss and certainly without effect upon resting cardiovascular parameters. The solenoid was driven by a function generator to allow modulation of the excursions of the device so that a clear expansion of the sinus could be seen macroscopically. The sinus was stretched with a sinusoidal pattern at a frequency , also for a period of 1 h. After completion of the period of stimulation 1 h was allowed to elapse prior to perfusion. In control animals, mechanical stimulation was carried out on the skin overlying the anterior temporalis muscle to assess any possible vibration effect of the device.
Perfusion
Cats were perfused transcardially with 1-1.5 1 of 0.9% saline after a bolus injection of 1000 IU of heparin and 0.5 ml of 1% sodium nitrite. This was followed by 2 1 of 4% paraformaldehyde in phosphate buffer (pH 7.4) and finally by 500-600 ml of 30% sucrose solution in phosphate buffer. The brain and cervical spinal cord were removed and stored in 50% sucrose with azide. Coronal sections (40 u.m) of the caudal medulla and upper cervical spinal cord were cut on a freezing microtome and every fifth section was collected for processing. Sections were cut from a block beginning at the level of the obex and ending at the C3 segment of the cervical cord.
The c-Fos procedure
Free-floating sections were incubated at 4°C for 3-7 days in a commercially available rabbit, polyclonal anti-body to Fos protein ('Ab-2\ Oncogene Science Ltd, Uniondale, NY, USA) in a 1:1000 dilution with 1% phosphate buffered horse serum, containing 0.1% bovine serum albumin and 0.2% Triton-XlOO. Fas-like immunoreactivity (hereafter simply called Fos) was visualized using standard avidin-biotin peroxidase immunohistochemical techniques. Following the primary incubation, sections were washed in 0.1 M phosphate buffer (pH 7.4) for 30 min and then incubated in a biotinylated goat anti-rabbit IgG (1:200 dilution) (Vector Labs, Peterborough, USA) for a minimum of 2 h at room temperature on a rotating table. Following the second incubation, the sections were washed again in 0. IM phosphate buffer (pH 7.4) for 30 min. The sections were incubated for 2.5 h in a 1:1000 dilution of ExtrAvidin-peroxidase (Sigma, London, USA) and then washed again in 0.1M phosphate buffer (pH 7.4) for 30 min. The sections were then incubated in 20 ml of 0.1 M phosphate buffer containing 0.05% diaminobenzidine (DAB) (Sigma), 0.005% of 4% ammonium chloride, 0.005% of 20% D-glucose and 0.02% of a 1% solution of nickel ammonium sulphate for 20 min (DAB reaction). The sections were then placed in a fresh identical 20 ml solution and 20 jxl of glucose oxidase (Sigma) was added to initiate the chromogenic reaction. The reaction was allowed to proceed until Fcs-positive nuclei could be clearly seen under the microscope. The DAB reaction product was visible as a black precipitate due to the presence of the nickel ammonium sulphate. Following this reaction the sections were washed two or three times in 0.1 M phosphate buffer (pH 7.4) to terminate the reaction and then mounted.
The Fas-positive cells were distinguished from the background by their black nickel enhanced nuclei. Using the procedure adopted by Hammond et al. (1992) , cells were only considered positive if the black precipitate of the DAB reaction within the cell nucleus was distinguishable from the background throughout a range of magnifications between X20 and X4. Fas-positive cells were plotted onto schematic drawings of the caudal medulla and upper cervical spinal cord modified from the atlases of Berman (1968) and Rexed (1954) . Control incubations in the presence of the antigen were not carried out in this series of experiments. However, the omission of the primary antibody in related experiments performed in this laboratory did not produce positive staining. Furthermore, preabsorption of the antibody with Fos protein has demonstrated its specificity in other studies.
Plotting and statistics
Distributions of cells were quantified for each individual animal by taking 10 sections at random, from each of the levels (TNC, Cl, C2 and C3) and plotting the label from a single side on to one of the schematic sections described above. The plotting was performed by one person who, although they had knowledge of the experimental design, was not aware of the experimental group to which each animal belonged. The data are reported as a median with interquartile (25%, 75%) ranges and have been compared using a Mann-Whitney U test in view of the fact that the c-Fos method as applied here can only yield non-continuous rather than interval data (Siegel, 1956) .
Results
All animals included in this study were successfully maintained within normal physiological limits for the anaesthetized cat. There was no difference in physiological data between the group which received mechanical stimulation and the one which received electrical stimulation ( Table 1 ). Some of the cats included here have provided data for a previous study (Kaube et al., 1993b) as this general group of studies is ongoing. In laminae I/IIo of the trigeminal nucleus caudalis (TNC) and Cl and C2 cervical spinal cord, electrical stimulation produced a median of 81 (range 76-114), 88 (range 84-107) and 92 (range 70-97) fas-positive cells, respectively (Table 2) , compared with unstimulated median control levels of seven, five and two cells positive, respectively. Mechanical stimulation of the SSS (n = 4) evoked a marked and reproducible Fos expression that was very similar to that seen with electrical stimulation, although less dense; in the superficial laminae of the caudal TNC the median number of cells was 38 (range 33^43) and in the dorsal horn of Cl, 32 cells (range 25^0) and of C2, 31 cells (range 19-42). This mechanical stimulation of the SSS produced no more than control levels of Fos expression at the level of C3. The positive control stimulus (consisting of mechanical stimulation the skin and musculature of the temporo-parietal region; n = 2) produced no significant levels of Fos expression (Fig. 1) .
Effect of sumatriptan
Treatment with sumatriptan (85 jag kg" 1 , intravenously; n = 3) essentially blocked the expression of Fos induced by mechanical stimulation of the superior sagittal sinus in all the above-mentioned areas. In the TNC, C| and C2 (laminae I/IIo) the median number of cells detected fell to 6 (range 5-6; P < 0.05), 13 (range 11-19; P < 0.05) and 9 (range 8-9; P < 0.05), respectively (see Table 3 and Figs 2 and 3) .
Discussion
These data demonstrate that activation of the neuronal 5HT ]Dlike receptor can inhibit trigeminally mediated neural traffic. The interpretation of these data is relatively straightforward, although several elements are required to describe the model system and its relevance to migraine. The Fos procedure is not specific for painful stimuli and the relevance of the data results from the model system employed rather than the method of analysis. It is crucial that the model employed has relevance to human vascular headaches as it does in these studies. The superior sagittal sinus has been used to activate the trigeminovascular system for several reasons. It is known that the sinus is pain-sensitive in humans. Electrical or mechanical displacement of the sinus and surrounding dura mater is reported as painful in patients (Feindel et al., 1960; McNaughton and Feindel, 1977) . Moreover, its innervation is by small fibres (Penfield and McNaughton, 1940; Kimmel, 1961; Keller et al., 1985) as is much of the dura mater in most species studied (Keller and Marfurt, 1991) . The trigeminal innervation of the sinus and dura mater is in turn taken by the ophthalmic division of the trigeminal nerve (Steiger et al., 1982) via the trigeminal ganglion to the trigeminal nucleus. Similarly, the large cranial vessels are pain-sensitive (Ray and Wolff, 1940; Wolff, 1963; Martins et al., 1993) and their innervation is also predominantly through the ophthalmic division of the trigeminal nerve (Liu-Chen et al., 1983) . This pattern of (Kaube el al., 19936) . This activation pattern is blocked after administration of sumatriptan.
intracranial vascular innervation is thought to underlie the expression of migraine as an often throbbing or pulsating pain. The superior sagittal sinus has thus been chosen as a structure for stimulation because of its known pain-sensitivity and because its size and position makes it accessible for study.
Stimulation of the superior sagittal sinus results in activation of neurons predominantly in the most caudal part of the trigeminal nucleus caudalis and in the dorsal horn of the Cl and C2 cervical spinal segments. This has been demonstrated by monitoring cellular activity (Lambert et al., 1988; Goadsby and Hoskin, 1996; Hoskin et al., 1996) , 2-deoxyglucose metabolism (Goadsby and Zagami, 1991) and c-Fos immunohistochemistry (Kaube et al., 1993/?; Hoskin et al., 1996) . Activation of these cells produces changes in cerebral blood flow (Lambert et al., 1988) just as does trigeminal stimulation in cat (Goadsby and Duckworth, 1987) and humans (Tran-Dinh et al., 1992) . Moreover, trigeminal ganglion stimulation Buzzi et al., 1991) and superior sagittal sinus stimulation lead to release of sensory neuropeptides into the cranial circulation (Zagami et al., 1990) in a similar manner to that seen in migraine Gallai et al., 1995) and cluster headache (Goadsby and Edvinsson, 1994; Fanciullacci et al., 1995) . Superior sagittal sinus stimulation, therefore, results in a pattern of activation of the trigeminal system that approximates that seen in migraine. The introduction into therapeutic use of the novel antimigraine agent sumatriptan and the demonstration of its utility in treating migraine attacks (Goadsby et al., 1991b; Subcutaneous Sumatriptan International Study Group, 1991) has resulted in considerable discussion as to its mode of action. The compound was developed as a 5HT agonist to constrict the dog saphenous vein and close cranial arteriovenous anastomoses (Humphrey et al., 1991; Saxena, 1991) on the basis that migraine was a primarily vascular disorder (Wolff, 1963) . Due to this design, there is a very small, yet well-recognized risk of cardiovascular problems associated with the use of drugs from this class of compounds. It has emerged that the 5HT m receptor (Hoyer et al., 1994; Hartig et al., 1996) at which sumatriptan is active may be present on trigeminal nerves. It has been shown that while sumatriptan inhibits protein plasma extravasation in the dura mater elicited by trigeminal ganglion stimulation, substance P-elicited plasma protein extravasation is not affected (Buzzi et al., 1991) . Similarly, sumatriptan blocks release of a peptide marker of trigeminal activation, calcitonin generelated peptide, in rat (Buzzi et al., 1991) and cat (Goadsby and Edvinsson, 1993) . Moreover, sumatriptan blocks calcitonin gene-related peptide release in migraine sufferers if their headache is aborted by the drug (Goadsby and Edvinsson, 1993) . Finally, the development of conformationally restricted analogues of sumatriptan that can block plasma protein extravasation at doses at which they have no vascular effects (Lee and Moskowitz, 1993) raises the possibility that the two effects could be dissociated in the clinical context too.
Since it is known that sumatriptan acts at both the 5HT 1B and 5HT, D receptors (Weinshank et al, 1992; Hoyer et al., 1994) it may be possible to design drugs that affect only one receptor and selectively target the trigeminal nerve (Rebeck et al., 1994) , although recent data suggest that both receptor subtypes may be present in both cranial vessels and nerves in different amounts (E. Hamel, personal communication) . Pharmacological approaches to dissecting the 5HT 1B/D -like receptors have been disappointing. This reflects, in part, species variations which have been addressed in a recent reclassification (Hartig et al., 1996) and the possibility that there is as yet an undiscovered receptor. The paradox remains that, whereas the vasoconstrictor effect of sumatriptan is blocked by methiothepin (Hamel and Bouchard, 1991) , a potent but not specific 5HT 1B/D antagonist (Peroutka and McCarthy, 1989; Schoeffter and Hoyer, 1989) , the response is not antagonized by metergoline either in vivo (Perren et al., 1991; Villalon et al., 1992) or in vitro (Bax et al., 1992) , although metergoline is more potent than methiothepin at the 5HT 1D receptor Waeber et al, 1988) . These data may simply be an amalgam of species variations and varying antagonist potencies of metergoline and methiothepin, although the intriguing possibility remains that a further 5HTl-like receptor is yet to be discovered. The development of the potent 5HT 1D antagonist GR127935 (Clitherow et al, 1994) does not hold an immediate key to this issue since it has some agonist activity itself (Pauwels and Colpaert, 1995) . Moreover, the specificity of GR127935 relates to what is known and if there is a further, as yet undefined, receptor in the 5HT1 class, GR127935 may also be active at that site. The experiments reported here were undertaken since it has been impossible to disentangle the vascular and neuronal effects of sumatriptan completely in vivo (Humphrey and Goadsby, 1994) . In this study, the sinus was held apart by the stimulator so that no vasoconstrictor effect could have contributed to the inhibition of c-Fos expression seen. The simplest reasonable conclusion is that sumatriptan inhibited trigeminal afferents by a direct neuronal mechanism at the peripheral terminal. An action at the trigeminal ganglion is unlikely since direct application of sumatriptan to trigeminal ganglion cells does not inhibit their activity (O'Shaughnessy et al, 1993) . Moreover, since it has been shown that to affect central trigeminal neurons, sumatriptan must be allowed to access such sites by artificial disruption of the blood-brain barrier (Kaube et al, 1993a; Shepheard et al, 1995) , central inhibition could not account for these results.
In summary, these studies demonstrate that mechanical distension of a pain-sensitive intracranial structure is capable of activating neurons in the caudal trigeminal nucleus caudalis and dorsal horns of the Cl and C2 cervical spinal cord. In the presence of a mechanical distension that would block any possible vasoconstrictor action of sumatriptan, inhibition of trigeminal neurons is seen. The only site available to mediate such an action would then be a neuronal site, probably on the trigeminal nerve terminals. These data suggest that a purely neuronally active inhibitor of trigeminal nerve responses would be capable of blocking trigeminal nucleus activation. Whether neuronally selective drugs would be effective in migraine and whether they would be superior to the current first generation 5HT 1B/D -like drugs remains a question that must be answered in the clinic with migraine patients. These data do not establish that nonvascular drugs would be superior but they do provide a rationale for their development and study in the clinic. The prospect of eliminating vascular effects from the management of migraine is sufficiently important alone to justify a clinical study of such compounds.
